Lv3
226 积分 2022-08-09 加入
Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic
12天前
已完结
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report
12天前
已完结
Type II RAF inhibitor tovorafenib for the treatment of pediatric low-grade glioma
13天前
已完结
Tovorafenib: First Approval
13天前
已完结
Operational characteristics of full random effects modelling (‘frem’) compared to stepwise covariate modelling (‘scm’)
13天前
已完结
FDA new drug approvals in Q2 2025
14天前
已完结
FDA approves 100th small-molecule kinase inhibitor
14天前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
20天前
已完结
Acral melanoma: new insights into the immune and genomic landscape
1个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
